Navigation Links
MaxCyte to Present at the BIO CEO & Investor Conference
Date:2/6/2008

GAITHERSBURG, Md., Feb. 6 /PRNewswire/ -- MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical, non-viral cell loading systems, announces Douglas Doerfler, President & CEO, will be presenting at the BIO CEO & Investor Conference in New York, Waldorf=Astoria, on Monday, February 11, 2008 at 11:45AM.

Mr. Doerfler will provide a brief corporate overview and discuss the company's preclinical and clinical product portfolio, partnering candidates, and enabling technology for therapeutic development and biotherapeutic manufacturing.

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary, non-viral, ex vivo cell loading technology provide safety, scalability and reproducibility capabilities which are fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). MaxCyte has recently partnered with Medinet (JP) to commercialize a cell based therapy to be launched in 2008. In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER).

For more information, visit http://www.maxcyte.com.


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. MaxCyte to Present at the Phacilitate Cell and Gene Therapy Forum 2008
2. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
3. HMS Holdings Corp. to Present at 2008 UBS Global Healthcare Services Conference
4. West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference
5. Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona
6. Vical to Present at BIO CEO and Investor Conference
7. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
8. NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
9. DURECT to Present at BIO CEO Investor Conference 2008
10. BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation
11. Bush Budget Represents Double Whammy Hit on U.S. Seniors Medicare-Financed Nursing Facility Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical Technologies ... with the addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice ... distribution and sales network, direct the efforts of the surgical sales teams, manage ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology: